{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T17:13:10Z","timestamp":1754154790103,"version":"3.41.2"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004586","name":"FAPERJ","doi-asserted-by":"publisher","award":["E-26\/211.262\/2019"],"award-info":[{"award-number":["E-26\/211.262\/2019"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jpba.2025.116861","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T19:06:23Z","timestamp":1744398383000},"page":"116861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pediatric formulations and challenges beyond technological development: Identification and in silico qualification of impurities in 5\u202fmg primaquine tablets"],"prefix":"10.1016","volume":"262","author":[{"given":"Thamara","family":"Carvalho Mendes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Eduarda Correia","family":"Furtado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana Johansson Soares","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivone de Jesus","family":"Nascimento Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fl\u00e1via Furtado","family":"Mendon\u00e7a Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diogo Dibo","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia Deris","family":"Prado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila Areias","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2025.116861_bib1","unstructured":"WHO, Global technical strategy for malaria 2016-2030, 2021 update, 2021. \u3008https:\/\/apps.who.int\/iris\/rest\/bitstreams\/1357541\/retrieve\u3009."},{"key":"10.1016\/j.jpba.2025.116861_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-017-1762-7","article-title":"A systematic review on malaria sero-epidemiology studies in the Brazilian Amazon: insights into immunological markers for exposure and protection","volume":"16","author":"Folegatti","year":"2017","journal-title":"Malar. J."},{"key":"10.1016\/j.jpba.2025.116861_bib3","doi-asserted-by":"crossref","unstructured":"BRASIL., Guia pr\u00e1tico de tratamento da mal\u00e1ria no Brasil.Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de Vigil\u00e2ncia Epidemiol\u00f3gica., 20 (2010) 1543\u20131553. https:\/\/doi.org\/10.1287\/mnsc.20.12.1543.","DOI":"10.1287\/mnsc.20.12.1543"},{"key":"10.1016\/j.jpba.2025.116861_bib4","unstructured":"ANVISA, List of reference drugs. List A: Drug products containing a single active pharmaceutical ingredient, (2023) 46. \u3008https:\/\/www.gov.br\/anvisa\/pt-br\/setorregulado\/regularizacao\/medicamentos\/medicamentos-de-referencia\/arquivos\/lista-a-incluidos-01092023.pdf\u3009."},{"key":"10.1016\/j.jpba.2025.116861_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics15041033","article-title":"Meeting challenges of pediatric drug delivery: the potential of orally fast disintegrating tablets for infants and children","volume":"15","author":"Golhen","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpba.2025.116861_bib6","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.xphs.2016.03.019","article-title":"An overview of pharmaceutical excipients: safe or not safe?","volume":"105","author":"Abrantes","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2025.116861_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1081\/PDT-100100545","article-title":"Influence of peroxide impurities in povidone and crospovidone on the stability of raloxifene hydrochloride in tablets: identification and control of an oxidative degradation product","volume":"5","author":"Hartauer","year":"2000","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jpba.2025.116861_bib8","doi-asserted-by":"crossref","unstructured":"United States Pharmacopeia, Primaquine phosphate tablets, (2024). http:\/\/doi.org\/10.31003\/USPNF_M69080_02_01.","DOI":"10.31003\/USPNF_M69080_02_01"},{"key":"10.1016\/j.jpba.2025.116861_bib9","doi-asserted-by":"crossref","unstructured":"United States Pharmacopeia, Primaquine phosphate, (2024). http:\/\/doi.org\/10.31003\/USPNF_M69050_06_01.","DOI":"10.31003\/USPNF_M69050_06_01"},{"key":"10.1016\/j.jpba.2025.116861_bib10","doi-asserted-by":"crossref","unstructured":"International Conference on Harmonisation, Q3B (R2): Impurities in New Drug Products, (2006) 12. \u3008https:\/\/doi.org\/10.1017\/CBO9781107415324.004\u3009.","DOI":"10.1017\/CBO9781107415324.004"},{"key":"10.1016\/j.jpba.2025.116861_bib11","unstructured":"International Conference on Harmonisation (ICH), Q1A (R2) Stability Testing of new Drug Substances and Products, 2003."},{"key":"10.1016\/j.jpba.2025.116861_bib12","unstructured":"ICH, Validation of analytical procedures Q2 (R2), (2022) 34."},{"key":"10.1016\/j.jpba.2025.116861_bib13","doi-asserted-by":"crossref","unstructured":"OCDE, Test No. 471:Bacterial Reverse Mutation Test, (1998) 11. \u3008https:\/\/doi.org\/10.1088\/0305-4470\/31\/2\/004\u3009.","DOI":"10.1088\/0305-4470\/31\/2\/004"},{"key":"10.1016\/j.jpba.2025.116861_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/1062936X.2015.1136680","article-title":"QSAR Toolbox \u2013 workflow and major functionalities","volume":"27","author":"Dimitrov","year":"2016","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.jpba.2025.116861_bib15","first-page":"372","article-title":"An introduction to read-across for the prediction of the effects of chemicals","author":"Dimitrov","year":"2010","journal-title":"Issues Toxicol."},{"key":"10.1016\/j.jpba.2025.116861_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14112324","article-title":"Drug stability: ICH versus accelerated predictive stability studies","volume":"14","author":"Gonz\u00e1lez-Gonz\u00e1lez","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpba.2025.116861_bib17","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jpba.2007.09.012","article-title":"Development and validation of UPLC method for determination of primaquine phosphate and its impurities","volume":"46","author":"Dongre","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.116861_bib18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00044-017-2101-9","article-title":"Discovery of a novel multifunctional carbazole\u2013aminoquinoline dimer for Alzheimer\u2019s disease: copper selective chelation, anti-amyloid aggregation, and neuroprotection","volume":"27","author":"Zhang","year":"2018","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.jpba.2025.116861_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.trac.2017.11.003","article-title":"Reactive impurities in large and small molecule pharmaceutical excipients \u2013 a review","volume":"101","author":"Zhang","year":"2018","journal-title":"TrAC - Trends Anal. Chem."},{"key":"10.1016\/j.jpba.2025.116861_bib20","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1208\/s12249-011-9677-z","article-title":"Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility","volume":"12","author":"Wu","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jpba.2025.116861_bib21","unstructured":"<45> Crospovidone. In The United States Pharmacopoeia and National Formulary USP 41-NF; The United States Pharmacopeial Convention, Inc.: Rockville, MD., (2023)."},{"key":"10.1016\/j.jpba.2025.116861_bib22","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/bms.1200020605","article-title":"The identification of 6-methoxy 8-aminoquionoline as a metabolite of primaquine in man","volume":"2","author":"Baty","year":"1975","journal-title":"Biol. Mass Spectrom."},{"key":"10.1016\/j.jpba.2025.116861_bib23","first-page":"290","article-title":"Selective toxicity of the antimalarial primaquine\u2014evidence for both uncoupling and inhibitory effects of a metabolite on the energetics of mitochondria and Its ATP synthase complex","volume":"3","author":"Baker","year":"1986","journal-title":"Pharm. Res. Off. J. Am. Assoc. Pharm. Sci."},{"key":"10.1016\/j.jpba.2025.116861_bib24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1128\/aem.47.3.540-543.1984","article-title":"Production of a novel dimeric metabolite of primaquine by Streptomyces rimosus","volume":"47","author":"Clark","year":"1984","journal-title":"Appl. Environ. Microbiol"},{"key":"10.1016\/j.jpba.2025.116861_bib25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0378-4347(97)00639-7","article-title":"Chromatographic studies on the isolation of peroxydisulphate oxidation products of primaquine","volume":"708","author":"Dua","year":"1998","journal-title":"J. Chromatogr. B Biomed. Appl."},{"key":"10.1016\/j.jpba.2025.116861_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0378-5173(93)90070-V","article-title":"Photochemical stability of biologically active compounds: V. Photochemical degradation of primaquine in an aqueous medium","volume":"100","author":"Kristensen","year":"1993","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2025.116861_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0378-5173(94)00221-P","article-title":", Formation of formaldehyde in polyethyleneglycol and in poloxamer under stress conditions","volume":"114","author":"Frontini","year":"1995","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2025.116861_bib28","first-page":"2271","article-title":"Identification of pharmaceutical impurities in formulated dosage forms","volume":"101","author":"Pan","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2025.116861_bib29","first-page":"2271","article-title":"Evaluation of hydroperoxides in common pharmaceutical excipients","volume":"101","author":"Wasylaschuk","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2025.116861_bib30","unstructured":"ICH, ICH guideline M7(R1) on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk, 2015. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m7r1-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit_en.pdf\u3009."},{"key":"10.1016\/j.jpba.2025.116861_bib31","unstructured":"OECD, Guidance Document on the Validation of (Quantitative) Structure-Activity Relationship [(Q)Sar] Models, (2007) 154."},{"key":"10.1016\/j.jpba.2025.116861_bib32","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0278-6915(96)00049-X","article-title":"Correlation of structural class with no-observed-effect levels: a proposal for establishing a threshold of concern","volume":"34","author":"Munro","year":"1996","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.jpba.2025.116861_bib33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.comtox.2018.07.002","article-title":"Utilizing Threshold of Toxicological Concern (TTC) with high throughput exposure predictions (HTE) as a risk-based prioritization approach for thousands of chemicals","volume":"7","author":"Patlewicz","year":"2018","journal-title":"Comput. Toxicol."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852500202X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852500202X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T20:21:44Z","timestamp":1753388504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170852500202X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":33,"alternative-id":["S073170852500202X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116861","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pediatric formulations and challenges beyond technological development: Identification and in silico qualification of impurities in 5\u202fmg primaquine tablets","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116861","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116861"}}